Media headlines about Lipocine (NASDAQ:LPCN) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Lipocine earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news articles about the specialty pharmaceutical company an impact score of 46.5476315946448 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Several research analysts have issued reports on the company. Canaccord Genuity set a $11.00 price objective on Lipocine and gave the stock a “buy” rating in a research report on Monday, August 7th. Roth Capital set a $38.00 price objective on Lipocine and gave the stock a “buy” rating in a research report on Thursday, August 10th. Finally, ValuEngine cut Lipocine from a “hold” rating to a “sell” rating in a research report on Thursday, August 10th.
Shares of Lipocine (LPCN) traded up 1.14% on Wednesday, hitting $3.56. The stock had a trading volume of 237,250 shares. The firm’s market cap is $73.27 million. The company’s 50-day moving average price is $3.96 and its 200 day moving average price is $4.04. Lipocine has a 12-month low of $3.03 and a 12-month high of $5.33.
Lipocine (NASDAQ:LPCN) last posted its quarterly earnings data on Monday, August 7th. The specialty pharmaceutical company reported ($0.31) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.01). On average, equities research analysts forecast that Lipocine will post ($0.96) earnings per share for the current fiscal year.
Lipocine Company Profile
Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.